Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Xencor, Inc. clinical trials
The registry lists 30 studies whose lead sponsor is Xencor, Inc.. 7 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2026.
Keep track of what changes. Save the Xencor, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Xencor, Inc..
- Xencor, Inc.30 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 30 of 30.
- Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsRecruitingNCT06276491Phase 1
- Study of XmAb942 in Healthy Participants and Participants With Ulcerative ColitisRecruitingNCT06619990Phase 1/2
- Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid TumorsRecruitingNCT07593092Phase 1
- Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaRecruitingNCT05433142Phase 1
- A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune DiseasesRecruitingNCT07284797Phase 1
- A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid ArthritisRecruitingNCT07230353Phase 1
- Study of XmAb412 in Healthy ParticipantsRecruitingNCT07713485Phase 1
- XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT05005728Phase 2
- Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLCTerminatedNCT06173505Phase 1/2
- Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic DermatitisTerminatedNCT06005792Phase 1
- Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsCompletedNCT05585034Phase 1
- A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesActive, not recruitingNCT05032040Phase 2
- Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic MalignanciesCompletedNCT02924402Phase 1
- A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid TumorsTerminatedNCT05996445Phase 1
- A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)CompletedNCT03752398Phase 1
- Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)TerminatedNCT05328102Phase 2
- Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung CancerTerminatedNCT04590781Phase 1/2
- A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCompletedNCT03849469Phase 1
- Study Evaluating AMG 424 in Subjects With Multiple MyelomaTerminatedNCT03445663Phase 1
- Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy VolunteersCompletedNCT04857866Phase 1
- A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsCompletedNCT03517488Phase 1
- A Study of XmAb®18087 in Subjects With NET and GISTCompletedNCT03411915Phase 1
- PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic MalignanciesCompletedNCT02730312Phase 1
- A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus ErythematosusCompletedNCT02725515Phase 2
- Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)CompletedNCT02725476Phase 2
- XmAb5871 Bioavailability StudyCompletedNCT02867098Phase 1
- Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195CompletedNCT02881853Phase 1
- Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic DermatitisCompletedNCT02148744Phase 1
- Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic LeukemiaCompletedNCT01161511Phase 1
- Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell LymphomaCompletedNCT00606645Phase 1